ACT Brief: Payment Infrastructure and Site Cash, Inspection Readiness Throughout Execution, and First Hemolytic Anemia Therapy

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of his interview, Patrick Mizer, chief technology officer at Ledger Run, traces fragmented contracts, outdated benchmarks, and disconnected systems behind payment inconsistency. With 80% of sites operating on six months or less of cash, the infrastructure redesign is urgent, and agentic AI is proving effective at removing manual invoice processing that historically consumed 60% of customer time.
• In part four of her series, Elizabeth Walsh, founder of Walsh Clinical Advisory, explained that inspection readiness is a continuous execution design condition, not a pre-submission activity, accumulating through proportionate risk-based decisions made by qualified personnel throughout the lifecycle. The TMF reflects how the program was actually run, not assembled before inspection; programs with active oversight, continuous self-review, and proactive gap management become inspection-ready through design and daily practice rather than remediation campaigns.
• The FDA approved Imaavy for warm autoimmune hemolytic anemia in patients 12 years and older who are corticosteroid-naive or experienced, marking the first therapy specifically approved for this rare, life-threatening autoantibody disease. The Phase II/III Energy trial showed three times as many Imaavy-treated patients achieved durable hemoglobin response by 24 weeks, with mean hemoglobin increase of one g/dL (grams per deciliter) at week one and 3.5-point higher mean fatigue reduction versus placebo.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.